贝纳利祖马布用于患有罕见和非标签性氨酸性疾病的成年人:为期52周的前性单中心研究
Aviv Talmon1, Oded Shamriz1,2, Limor Rubin1
1Allergy and Clinical Immunology Unit, Department of Medicine, Hadassah Medical Organization, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Frontiers in immunology
|November 10, 2025
概括
贝纳利祖马布有效地治疗了成年人罕见的乙氨基酸性疾病,导致症状控制和停用皮质类固醇. 这项研究强调了它在喘和EGPA以外的各种疾病中的潜力.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 由于异质性和有限的向疗法,罕见的乙酸性疾病存在管理挑战.
- 贝纳利祖马布是一种抗IL-5受体单克隆抗体,已被批准用于严重的酸性喘和EGPA.
- 它在其他乙酸性疾病中的有效性仍未得到充分研究.
研究的目的:
- 为了评估本拉利祖马布在患有罕见非喘性异osinophilic 疾病的成年人的52周疗效和安全性.
- 评估本拉利祖马布对外围乙蛋白细胞数量,组织透,症状和皮质类固醇使用的影响.
主要方法:
- 一个单中心,前性,开放标签研究,涉及17名患有多种类型的菌性疾病的成年人.
- 贝纳利祖马布 (30毫克每4周) 服用了24周,反应持续至52周.
- 主要终点:氨基酸细胞数量或组织透率降低≥50%,次要终点包括症状改善和安全性.
主要成果:
- 在17名患者中,有16名患者实现了临床缓解,并完全减少了外围乙氨基酸.
- 所有完成者都停止了皮质类固醇治疗,显示出显著的症状控制.
- 本拉利祖马布在诸如乙性白血病,毛囊炎,阴道炎和IgG4相关疾病等疾病中表现出有效性;由于轻度肝酶升高,有一次部分反应和一次中止治疗.
结论:
- 贝纳利祖马布是安全的,耐受性很好,并且在治疗一系列罕见的乙酸性疾病时有效.
- 它可以促进皮质类固醇的停用,并改善在这些具有挑战性的条件下控制症状.
- 这些发现表明本拉利祖马布的治疗潜力更广泛,这需要在罕见的酸性疾病中进行进一步的研究.
相关概念视频
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K
01:30Asthma-IV: Diagnostic and Management
3.1K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.1K
01:19Antiasthma Drugs: Leukotriene Modifiers
1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.7K
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
1.6K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
1.6K
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
1.7K
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
1.7K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
428
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
428